[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 286,640
  • Shares Outstanding, K 56,204
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,440 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.61

Options Overview Details

View History
  • Implied Volatility 114.53% (+41.88%)
  • Historical Volatility 51.03%
  • IV Percentile 27%
  • IV Rank 9.44%
  • IV High 633.46% on 11/10/25
  • IV Low 60.43% on 04/21/26
  • Expected Move (DTE 31) 0.98 (21.39%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 122
  • Volume Avg (30-Day) 383
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 3,911
  • Open Int (30-Day) 8,974
  • Expected Range 3.59 to 5.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 5
  • High Estimate $-0.32
  • Low Estimate $-0.40
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.49 +3.67%
on 05/18/26
5.68 -18.12%
on 05/06/26
-0.78 (-14.43%)
since 04/17/26
3-Month
4.49 +3.67%
on 05/18/26
7.50 -37.93%
on 02/23/26
-2.01 (-30.21%)
since 02/18/26
52-Week
2.77 +68.05%
on 07/02/25
7.82 -40.47%
on 11/24/25
+1.47 (+45.92%)
since 05/16/25

Most Recent Stories

More News
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:...

TARA : 4.59 (-10.00%)
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

      TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients...

TARA : 4.59 (-10.00%)
Protara Therapeutics: Q1 Earnings Snapshot

Protara Therapeutics: Q1 Earnings Snapshot

TARA : 4.59 (-10.00%)
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion...

TARA : 4.59 (-10.00%)
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.   (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare...

TARA : 4.59 (-10.00%)
Protara Therapeutics: Q4 Earnings Snapshot

Protara Therapeutics: Q4 Earnings Snapshot

TARA : 4.59 (-10.00%)
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients  Company expects...

TARA : 4.59 (-10.00%)
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial...

TARA : 4.59 (-10.00%)
Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.   (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

TARA : 4.59 (-10.00%)
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment...

TARA : 4.59 (-10.00%)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 5.37
2nd Resistance Point 5.29
1st Resistance Point 5.20
Last Price 4.59
1st Support Level 5.02
2nd Support Level 4.94
3rd Support Level 4.84

See More

52-Week High 7.82
Fibonacci 61.8% 5.89
Fibonacci 50% 5.30
Fibonacci 38.2% 4.70
Last Price 4.59
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.